The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.
 
Elisa A. Rozeman
No Relationships to Disclose
 
Christian U. Blank
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Alexander Christopher Jonathan Van Akkooi
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Pia Kvistborg
Consulting or Advisory Role - Merck (Inst); Neon Therapeutics (Inst); Personalis (Inst)
 
Lorenzo Fanchi
No Relationships to Disclose
 
Johannes V. Van Thienen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst)
 
Bauke Stegenga
Employment - Bristol-Myers Squibb
 
Brian Lamon
Employment - Bristol-Myers Squibb
 
John B. A. G. Haanen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst)
 
Ton Schumacher
No Relationships to Disclose